

BENJAMIN YOUNG, MD, PhD, AAHIVS
Curriculum Vitae

CURRENT ADDRESS:

International Association of Providers of AIDS Care
1424 K St. NW, Suite 200, Washington, DC 20005
byoung@iapac.org

Apex Research, LLC
300 South Jackson Street, Suite 230, Denver, Colorado 80209

EDUCATION:

B.A. University of California, San Diego. 1983.
Ph.D. University of Colorado, Boulder. 1990.
M.D. University of Colorado, Health Sciences Center. 1992.

EXPERIENCE:

1986-1990 Graduate Student
Department of Molecular, Cellular and Developmental Biology
University of Colorado, Boulder

1990-1991 Post-doctoral Research Associate
Howard Hughes Medical Institute, University of Colorado, Boulder

1989-1992 Medical Scientist Training Program, School of Medicine
University of Colorado Health Sciences Center (UCHSC)

1992-1995 Resident in Internal Medicine. UCHSC

1995-1998 Fellow in Infectious Diseases, UCHSC

1998-2006 Clinical Instructor of Medicine, UCHSC

1998-2012 Attending Physician. Rose Medical Center, Denver, Colorado

1998-present Principal Investigator
HIV Outpatient Study, Centers for Disease Control and Prevention

2006-present Clinical Assistant Professor of Medicine, University of Colorado Denver

2009-2011 Head of Medical Affairs
Health Connections International, Amsterdam

2009-2012 Medical Director
Rocky Mountain CARES, Denver, Colorado

2012-present Adjunct Professor
Josef Korbel School of International Studies. University of Denver.

Apex Family Medicine/Apex Research
Denver, Colorado

2012-2014 Vice President and Chief Medical Officer
International Association of Providers of AIDS Care. Washington, DC

2014-present Senior Vice President and Chief Medical Officer
International Association of Providers of AIDS Care. Washington, DC

HONORS AND AWARDS:

1981-1982 President's Undergraduate Fellow, University of California.
1982-1983 Departmental Honors and Distinction
Department of Biology, University of California, San Diego
1987-1988 University Fellow, University of Colorado
1990-1992 Fellow, Medical Scientist Training Program. University of Colorado
1992 Graduation with Honors. School of Medicine. University of Colorado.
2002-2006 "Denver's Top Doctors". 5280 Magazine, Denver, Colorado.
2005 Outstanding HIV/AIDS Clinician. TheBody.com HIV Leadership Award.
2006 "Hero" of Project Results Colorado for work on the global HIV epidemic
2011 Peak Performers Award for Excellence in Infectious Diseases.
Rocky Mountain Hospital Medicine Symposium
2012 "Clinical Academic Publication Award", University of Colorado
2016 "IAPAC 150", Geneva, Switzerland

HONORARY SOCIETIES:

Alpha Omega Alpha

PROFESSIONAL SOCIETIES:

Infectious Disease Society of America
HIV Medicine Association
American Academy of HIV Medicine
International AIDS Society
International Association of Physicians in AIDS Care

LICENSURE:

Colorado (#34102; expires 30 April 2019)

CERTIFICATION:

Internal Medicine (1997)
Infectious Diseases (2000)
HIV Medicine (2004- AAHIVM)

PROFESSIONAL SERVICE:

1998-2002 Institutional Research Review Board
Infection Control Committee
Rose Medical Center, Denver, CO.

2005-2006 Physician Faculty. Basic Antiretroviral Therapy Course; Advanced ART and
Opportunistic Infection Course. AIDS Knowledge Hub. Kiev, Ukraine.
American International Health Alliance, International Association of Physicians in AIDS
Care.

Co-director. Tuberculosis and HIV Treatment Training course. St Petersburg, Russia.
American International Health Alliance; USAID

- Co-director. Advanced HIV Therapy Training Course. AIDS Knowledge Hub. St Petersburg, Russia. American International Health Alliance, International Association of Physicians in AIDS Care.
- 2006 Co-Chief Editor, Fundamentals of HIV Medicine. American Academy of HIV Medicine
- 2007 Physician Faculty. Workshop on antiretroviral therapy, curriculum development. Moscow City AIDS Center, Russia. American International Health Alliance
- Physician Faculty. On-site mentoring, antiretroviral therapy. Dnepropetrovsk Oblast, Ukraine. American International Health Alliance, Clinton Foundation
- 2008 International Faculty. HIV Professional Development Workshop series. Moscow, Russia. [Russian Ministry of Health, USAID, GlaxoSmithKline]
- Co-Director. Advanced Antiretroviral Therapy and Training of Trainers Course. Central Asian AIDS Control Project. Tashkent, Uzbekistan.
- Co-Director. Training of Trainers Course. Central Asian AIDS Control Project. Samarkand, Uzbekistan.
- 2009-2011 Head of Medical Affairs, Health Connections International. Amsterdam, The Netherlands.
- 2009-2012 Founder and Medical Director, Rocky Mountain CARES. Denver, Colorado.
- 2010-2012 International Faculty. HIV Professional Development Workshop series. Saint Petersburg, Moscow and Irkutsk, Russia. [American International Health Alliance, Russian Federation Ministry of Health, USAID, Viiv Healthcare]
- 2012 Co-Chief Editor, 2012 Fundamentals of HIV Medicine. American Academy of HIV Medicine
- Scientific Advisory Board, 2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care. Washington DC.
- 2013-present Medical Editor, Journal of the International Association of Physicians in AIDS Care
- Medical Consultant, AIDSInfoNet.org
- 2015-present HIV Clinical Guidelines Development Group. World Health Organization. HIV/AIDS Department, Geneva, Switzerland.
- 2015 Treatment Section Chief, International Advisory Panel on HIV Care Continuum Optimization. International Association of Providers of AIDS Care.
- 2016 Lead author, United Nations Joint Programme on HIV/AIDS (UNAIDS) Task Shifting Initiative
- 2016-2017 HIV Prevention Work Group. Colorado Department of Public Health and Environment
- Principle, Global Consensus Statement on the Science of HIV in the Context of the Criminal Law, 2017. With United Nations Joint Programme on HIV/AIDS (UNAIDS), International AIDS Society

REVIEWER

1. Journal of the International Association of Providers of AIDS Care
2. Journal AIDS
3. Lancet Infectious Diseases
4. PLoS One
5. Antiviral Therapy
6. Journal of Antimicrobial Chemotherapy
7. Clinical Infectious Diseases

PEER REVIEWED PUBLICATIONS:

1. ME King, A Naporn, **B Young** and SB Howell. 1984. Modulation of cytarabine uptake and toxicity by dipyrnidamole. *Cancer Treat. Rep.* 68, 361-366.
2. TC Chan, **B Young**, ME King, R Taetle and SB Howell. 1985. Modulation of the activity of PALA by dipyrnidamole. *Cancer Treat. Rep.* 69, 425-430.
3. GA Freyer, J Arenas, KK Perkins, HM Furneaux, L Pick, **B Young**, R Roberts, and J Hurwitz. 1987. In vitro formation of a lariat structure containing a G^{2'}-5'-G linkage. *J. Biol. Chem.* 262, 4267-4273.
4. **B Young** and TR Cech. 1989. Specificity for 3'-5'-linked substrates in RNA-catalyzed RNA polymerization. *J. Mol. Evol.* 29, 480-485.
5. **B Young** and B Hicke. 1990. Delta virus as a cleaver. *Nature* 343, 28.
6. **B Young**. 1990. Enzyme-substrate interactions in the catalytic RNA from *Tetrahymena thermophila*. Ph.D. thesis, University of Colorado, Boulder, Colorado.
7. **B Young**, D Herschlag and TR Cech. 1991. Mutations in a nonconserved sequence of the *Tetrahymena* ribozyme increase activity and specificity. *Cell* 67, 1007-1019.
8. JD Bisognano, **B Young**, JM Brown, EA Gill, FC Fang, LS Zisman. 1997. Diverse presentations of aberrant origin of the right subclavian artery: two case reports. *Chest* 112, 1693-1697.
9. **B Young**, S Johnson, M Bakhtiari, D Shugarts, R Young, DR Kuritzkes. 1998. Resistance mutations in protease and reverse transcriptase genes of HIV-1 isolates from patients failing combination antiretroviral therapy. *J Inf Dis*, 178: 1497-1501.
10. **B Young**, DR Kuritzkes. 1999. Reply to Monno, et al. *J Inf Dis*.180:570-1.
11. DR Kuritzkes, A Sevin, **Young B**, M Bakhtiari, M St. Clair, E Connick, A Landay, J Spritzler, H Kessler, MM Lederman for the ACTG 315 protocol team. 2000. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315. *J Inf Dis.* 181: 491-7.
12. KA Lichtenstein, D Ward, AC Moorman, KM Delaney, **B Young**, FJ Palella, K Wood, S Holmberg and the HOPS Investigators. 2001. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. *AIDS*. 2001 Jul 27; 15(11):1389-98.
13. ER Brown, S MaWhinney, RH Jones, K Kafadar, **B Young**. 2001. Improving the fit of bivariate splines when estimating longitudinal immunological and virological markers in HIV patients with individual antiretroviral treatment strategies. *Statistics in Med* 20: 2489-2504.
14. **B Young**, M Fischl, HM Wilson, et al. 2002. Open-label study of a twice-daily indinavir 800 mg/ ritonavir 100 mg regimen in protease inhibitor-naïve HIV-infected adults. *J Acquir Immune Defic Syndr*; 31: 478-82.
15. GA McComsey, JS Huang, I Woolley, **B Young**, PE Sax, M Gerber, S Swindells, H Bonilla, G Gopalakrishnan. 2004. Fragility fractures in HIV-infected subjects: an area for improvement. *J Int Assoc Physicians AIDS Care (Chic Ill)*. 2004 Jul-Sep;3(3):86-91.
16. T Hawkins, C Geist, **B Young**, A Giblin, R Mercier, K Thornton, R Haubrich. 2005. Efavirenz (EFV) induced CNS side effects persist for one year compared to protease inhibitors (PIs). *HIV Clin Trials*. 2005 Jul-Aug; 6(4):187-96.

17. JE Gallant, AE Rodriguez, W Weinberg, **B Young**, D Berger, ML Lim, Q Liao, L Ross, J Johnson, MS Shaefer. 2005. Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV-Infected Antiretroviral-Naive Subjects. *J Infect Dis.* 2005 Dec 1;192(11):1921-30. Epub 2005 Oct 25.
18. **B Young**, C Armon, R Baker, P Wiedle, A Moorman, K Wood, and the HIV Outpatient Study (HOPS) Investigators. 2006. Long-term assessment of the safety and tolerability of didanosine combined with tenofovir DF in ambulatory HIV-1 infected adult individuals. *AIDS Patient Care and STDs.* 20 (4); 238-244.
19. J Eron, P Yeni, J Gathe, V Estrada, E DeJesus, S Staszewski, P Lackey, K Katlama, **B Young**, L Yau, D Sutherland-Phillips, P Wannamaker, C Vavro, L Patel, J Yeo, M Shaefer. The KLEAN Study: fosamprenavir/ritonavir versus lopinavir/ritonavir, each in combination with the abacavir/lamivudine tablet, for the initial treatment of HIV infection over 48 weeks. *Lancet.* 2006.
20. K Buchacz, **B Young**, RK Baker, A Moorman, JS Chmiel, KC Wood, JT Brooks for the HOPS Investigators. 2006. Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort. *J Acquir Immune Defic Syndr* 43(5): 626-628.
21. **B Young**, K Buchacz, RK Baker, A Moorman, JS Chmiel, KC Wood, JT Brooks for the HOPS Investigators. 2007. Renal function in tenofovir-exposed and -unexposed patients receiving highly active antiretroviral therapy (HAART) in the HIV Outpatient Study (HOPS) cohort. *J Int Assoc Physicians AIDS Care.* 2007: 6 (3): 178-187.
22. HY Huang, ES Daar, P Sax, **B Young**, P Cook, P Benson, C Cohen, A Schribner, H Hu. 2008. The Prevalence of Transmitted Antiretroviral Drug Resistance in Treatment Naïve Patients and Factors Influencing First-Line Treatment Regimen Selection. *HIV Medicine* 9: 285-293.
23. **B Young**, K Squires, P Patel, E DeJesus, N Bellos, D Berger, DH Sutherland Phillips, Q Liao, M Shaefer, P Wannamaker. 2008. First large, multicenter, open-label study utilizing *HLA-B*5701* screening for abacavir hypersensitivity in North America. *AIDS.* 22:1673-1681.
24. J Winston, G Deray, T Hawkins, L Szczech, C Wyatt and **B Young**. Kidney disease in patients with HIV infection and AIDS. *Clin Infect Dis.* 2008; 47: 1449-1457
25. J Campbell, **B Young**. Utilization of screening colonoscopy in ambulatory HIV-infected patients. *J Int Assoc Physicians AIDS Care.* 2008 Dec;7(6):286-288. Epub 2008 Nov 17
26. E DeJesus, **B Young**, JO Morales Ramirez, L Sloan, DJ Ward, JF Flaherty, R Ebrahimi, J-F Maa , K Reilly, J Ecker, D McColl, D Seekins, JA Farajallah. Simplification of Antiretroviral Therapy (ART) with Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF) Single-Tablet-Regimen vs. Continued Unmodified ART in Virologically-Suppressed, HIV-1-Infected Patients. *J Acquir Immune Defic Syndr.* 2009 Jun 1;51(2):163-74.
27. **B Young**, K Buchacz, RK Baker, A Moorman, JS Chmiel, KC Wood, JT Brooks for the HOPS Investigators. 2009. Renal function in patients with pre-existing renal disease receiving tenofovir-containing HAART in the HIV Outpatient Study (HOPS) cohort. *AIDS Patient Care STDs.* 2009 Aug;23(8):589-92.
28. J Gray, **B Young**. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review. 2009. *AIDS Patient Care and STDs.* 2009 Sep; 23(9):689 -90.
29. Eron JJ, **Young B**, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P; SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. *Lancet.* 2010 Jan 30;375(9712):396-407. Epub 2010 Jan 12.

30. Buchacz K, Baker RK, **Young B**, Brooks JT; the HIV Outpatient Study (HOPS) Investigators. Changes in the Use of HIV Antiretroviral Resistance Testing in a Large Cohort of U.S. Patients, 1999 to 2006. *J Acquir Immune Defic Syndr*. 2010 Apr;53(5):625-32.
31. Squires KE, **Young B**, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS, ARIES Study Team. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. *HIV Clin Trials*. 2010 Mar-Apr;11(2):69-79.
32. Squires KE, **Young B**, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer, MS for the ARIES study team. Similar efficacy and tolerability of atazanavir (ATV) compared to atazanavir/ritonavir (ATV/RTV, r), each with abacavir/lamivudine (ABC/3TC) after initial suppression with ABC/3TC + ATV/r in HIV-infected patients. *AIDS*. 2010 Jul 5. [Epub ahead of print]; 2010 Aug 24;24(13):2019-2027.
33. Campbell JL, Ruano AL, Samayoa, B, Estrada Muy DL, Arathoon E, **Young B**. Adherence to antiretroviral therapy in an urban, free-care HIV clinic in Guatemala City, Guatemala. *J Int Assoc Physicians AIDS Care*. 2010 Nov 12. [Epub ahead of print]. 9(6):360-395.
34. **B. Young**, T. Vanig, E. DeJesus, T. Hawkins, M. St. Clair, L. Yau, B. Ha, and the SHIELD study team. A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Patients: 48-Week Results of the SHIELD Trial. *HIV Clinical Trials*. 2010. 11(5): 260-269
35. C Cohen, E DeJesus, A Lamarca, **B Young**, L Yau, L Patel, C Vavro, MB Wire, P Wannamaker, M Schaefer. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS Trial. *HIV Clinical Trials*. 2010. 11(5): 239-247.
36. **B Young**, C Dao, K Buchacz, R Baker, JT Brooks. Higher and Increasing Rates of Fracture among HIV-infected Persons in the HIV Outpatient Study (HOPS) Compared to the General U.S. Population, 1994-2008. *Clin Infect Dis*. 2011 Apr; 52(8):1061-1068. Epub 2011 Mar 10.
37. **B Young**, S Fransen, KS Greenberg, A Thomas, S Martens, M St Clair, CJ Petropoulos, B Ha. Transmission of integrase strand-transfer inhibitor, multi-drug resistant HIV-1: Case report and natural history of response to raltegravir-containing antiretroviral therapy. *Antivir Ther*. 2011;16(2):253-6.
38. JJ Eron, JK Rockstroh, J Reynes, J Andrade-Villanueva, JV Ramalho-Madruga, L-G Bekker, **B Young**, C Katlama, JM Gatell-Artigas, JR Arrivas, M Nelson, H Campbell, J Zhao, AJ Rodgers, ML Rizk, L Wenning MD Miller, D Hazuda, MJ DiNubile, R Leavitt, R Isaacs, MN Roberson, P Sklar, BY Nguyen. QDMRK investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomized, active-controlled, phase 3 non-inferiority trial. *Lancet Infect Dis*. 2011 Dec;11(12):907-15. Epub 2011 Sep 18.
39. **B. Young**, T. Vanig, E. DeJesus, T. Hawkins, M. St. Clair, B. Stancil, B. Ha, and the SHIELD study team. 96-Week Results of a Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Patients: the SHIELD Trial. *HIV Clin Trials* 2011;12(4):228-233.
40. J van Lunzen, F Maggiolo, JR Arribas, A Rakhmanova, P Yeni, **B Young**, JK Rockstroh, S Almond, I Song, C Bothers, S Min. Rapid and sustained antiviral response with once-daily dolutegravir in combination therapy in antiretroviral-naïve adults: planned interim 48-week results from SPRING-1 (ING112276), a partially blinded, dose-ranging, randomised, phase IIb clinical trial. *Lancet Infect Dis*. 2012 Feb;12(2):111-8. Epub 2011 Oct 20.
41. RM Novak, JT Richardson, K Buchacz, JS Chmiel, MD Durham, FJ Palella, A Wendrow, K Wood, **B Young**, JT Brooks and the HOPS Investigators. Immune Reconstitution Inflammatory Syndrome (IRIS) in the HIV Outpatient Study (HOPS): Incidence and Implications for Mortality. *AIDS*, 2012 Mar 27;26(6):721-30
42. K. Buchacz, DJ Ward, RK Baker, F Palella, JS Chmiel, **B Young**, BG Yangco, R. Novak and J. Brooks. Trends in Decline of Antiretroviral Resistance among ARV-experienced Patients in the HIV Outpatient Study (HOPS): 1999-2008. *AIDS Res Treat*, vol. 2012, 2012:230290 Epub Mar 14, 2012 Article ID 230290

43. KE Squires, **B Young**, E DeJesus, N Bellos, D Murphy, D Ward, HH Zhao, LL Ross, MS Shaefer for the ARIES study team. ARIES 144 Week Results: Durable Virologic Suppression in HIV-infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine. *HIV Clin Trials*. 2012 Sep-Oct;13(5):233-44. doi: 10.1310/hct1305-233.
44. **B Young**, K Squires, L Ross, L Santiago, L Sloan, H Zhao, B Wine, GE Pakes, D Margolis M Shaefer for the ARIES Study team. Inflammatory Biomarker Changes and Their Correlation With Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-naïve HIV-infected Patients Treated for 144 weeks with Abacavir/Lamivudine/Atazanavir With or Without Ritonavir in ARIES. *AIDS Res Hum Retroviruses*. 2012 Oct 8. [Epub ahead of print]
45. J Zuniga and **B Young**. Achieving Improvements across the Treatment Cascade: A Clinical Management Algorithm Based on IAPAC's Entry into and Retention in Care and Antiretroviral Therapy Adherence Guidelines. *J Int Assoc Providers AIDS Care*. 2013. 12(1): 15-17.
46. KR Amico, JM Zuniga, I Wilson, R Gross, **B Young**. Provider Guidance for Linking Patients to Antiretroviral Therapy Adherence Interventions: Recommendations from an IAPAC Advisory Committee on Adherence Monitoring and Support. *J Int Assoc Providers AIDS Care*. 2013 Mar; 12(2): 79-83.
47. E Tedaldi, J Richardson, R Debes, **B Young**, JS Chmiel, MD Durham, JT Brooks, K Buchacz and the HOPS Investigators. Retention in care within one year of initial HIV care visit in a multisite U.S. cohort: who's in and who's out? *J Int Assoc Providers AIDS Care*. 2014 May-Jun;13(3):232-41. Epub 2014 Feb 3.
48. Battalora, L., Thomas, A., Wine, B., Ha, B., & **Young, B.** (2014). Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial. *World Journal of AIDS*, 2014. Vol.4 No.1 (2014), Article ID:43424
49. **B Young**, JM Zuniga, JSG Montaner, K Mayer. Controlling the HIV Epidemic with Antiretrovirals: Moving from Aspirations to Implementation. *Clin Infect Dis* 2014;59(S1):S1-2.
50. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, **International Association of Providers of AIDS Care**, the National Minority AIDS Council, and Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States, 2014. <http://stacks.cdc.gov/view/cdc/26062>.
51. A Pineirua, J Sierra-Madero, P Cahn, RN Guevara Palmero, E Martinez, **B Young**, C del Rio. (2015). The HIV care cascade in Latin America: Challenges and Opportunities. *Lancet Infect Dis* 2015; 15:833-839.
52. K Buchacz, **B Young**, F Palella, C Armon, JT Brooks. (2015). Trends in the use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naïve persons in the HIV Outpatient Study, 1999-2011. *J Antimicrobial Chemotherapy*. 2015 Aug;70(8):2337-46. doi: 10.1093/jac/dkv120. Epub 2015 May 15.
53. R Granich, S Gupta, B Hersh, B Williams, J Montaner, **B Young**, JM Zuniga. (2015) Antiretroviral treatment and AIDS-related deaths in the top 30 countries with the highest burden of estimated AIDS deaths, 1990-2013. *PLoS One*. 2015 Jul 6;10(7):e0131353.
54. **B Young**, K Squires, K Tashima, K Henry, S Schneider, A LaMarca, HH Zhao, LL Ross, MS Shaefer. (2015). Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. *HIV Clinical Trials*. 2015 Jul 2:1528433614Z0000000017. [Epub ahead of print]
55. L Battalora, K Buchacz, C Armon, ET Overton, J Hammer, P Patel, JS Chmiel, TJ Bush, JT Brooks, **B Young**, the HIV Outpatient Study (HOPS), SUN Study Investigators. (2015) Low bone mineral density is associated with increased risk of incident fracture in HIV-infected adults. *Antivir Ther*. 2015 Jul 21. doi: 10.3851/IMP2979. [Epub ahead of print]

56. **Young, B.**, Hart, R. L., Buchacz, K., Scott, M., Palella, F., & Brooks, J. T. (2015). HIV Viral Load Monitoring Frequency and Risk of Treatment Failure Among Immunologically Stable HIV-Infected Patients Prescribed Combination Antiretroviral Therapy. *J Int Assoc of Provid of AIDS Care*, 2325957415600799.
57. International Advisory Panel on HIV Care Continuum Optimization. (2015). IAPAC Guidelines for optimizing the HIV care continuum for adults and adolescents *J Int Assoc of Provid of AIDS Care* 2015 Nov 2. pii: 2325957415613442. [Epub ahead of print]
58. Squires KE, **Young B**, Santiago L, Dretler RH, Walmsley SL, Zhao HH, et al., (2017). Response by gender of HIV-1–infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. *HIV/AIDS - Research and Palliative Care*. 2017;9 51–61

REVIEWS and BOOK CHAPTERS

1. **B Young**, DR Kuritzkes. 1999. Viral Kinetics: Implications for Treatment. *J Acquir Immune Defic Syndr* 13 (suppl 1): S11-S17.
2. **B Young**. 2000. A Look to the Horizon: New Targets and New Drugs. *Positive 4 Positives*. August 2000. Cheyenne, Wyoming.
3. **B Young**, DR Kuritzkes. 2001. Resistance to HIV Protease Inhibitors. In Protease Inhibitors in AIDS Therapy, Chapter 12, pp 257- 282. R Ogden, CW Flexner, Eds.
4. **B Young**, KS Greenberg. 2001. HIV: Diagnostic and Clinical Strategies. In Physician Desk Reference 2001, HIV Disease Management Guide. Section I, pp 101-122.
5. **B Young**. 2003. Lipodystrophy and Metabolic Complications of HIV and Antiretroviral Therapies. STEP. Seattle, Washington.
6. **B Young**. 2003. Clinical Expectations of Efficacy: Issues of PI Potency and Efficacy. *Adv Studies Med*. 3 (Nov):S11-S16.
7. **B Young**, M Markowitz. 2004. Do New Protease Inhibitors Offer Improved Clinical Effectiveness. Issues of PI Potency and Efficacy. *J Acquir Immune Defic Syndr*. 35 (Suppl 1): S3-S12.
8. **B Young**. 2004. The Role of Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Backbones in Antiretroviral Therapy. *J Acquir Immune Defic Syndr*. 2004 Sep 1;37 Suppl 1:S13-20.
9. KS Greenberg, **B Young**. 2004. Effective regimens for the treatment of HIV. *North Am. Pharmacotherapy*.
10. **B Young**. 2005. Mixing new cocktails: Drug interactions in antiretroviral regimens. *AIDS Patient Care and STDs*. 2005 May; 19 (5):286-97.
11. **B Young**, JK Carmichael, D Johnson, T Mills. 2006. PA Update: DHHS Guidelines for the Treatment of HIV Infection. *J. Am Assoc. Phys Assist.* (Jan) Suppl. 1: 3-13.
12. S Livingston, **B Young**, and M Markowitz. HIV Life Cycle. In: *AAHIVM Fundamentals of HIV Medicine*, 2012 Edition. Washington DC: American Academy of HIV Medicine. 2012: [pp 330-334].
13. A Keller, N Bellos and **B Young**. Classes of Antiretrovirals. In: *AAHIVM Fundamentals of HIV Medicine*, 2012 Edition. Washington DC: American Academy of HIV Medicine. 2012: [pp 365-387].
14. L Battalora and **B Young**. 2012. Bone Health and HIV. In: *AAHIVM Fundamentals of HIV Medicine*, 2012 Edition. Washington DC: American Academy of HIV Medicine. 2012:[pp 770-783].
15. TasP/PrEP Consensus Statement Advisory Committee. Controlling the HIV Epidemic With Antiretrovirals. Treatment as Prevention and Pre-exposure Prophylaxis. IAPAC Consensus Statement. 26 July 2012.
16. L Battalora, J Spear, J., and **B Young**. 2012. HIV and Aging: An Evolving Challenge for the Oil and Gas Industry. In *International Conference on Health, Safety and Environment in Oil and Gas Exploration and Production*.
17. EM Gardner, **B Young**. Viewing changes in the HIV care cascade over time. *Lancet Infect Dis*. 2013 Sep 26. [Epub ahead of print]
18. Libre JM and **B Young**. Unplanned Antiretroviral Treatment Interruptions, Genetic Barrier, and Development of Resistance. *HIV Medicine*. *HIV Medicine* (2014), 15, 193–195

19. Battalora, L. A., **Young, B.**, & Overton, E. T. (2014). Bones, Fractures, Antiretroviral Therapy and HIV. *Current Infect Dis Rep.*, 16(2), 1-6.
20. **B Young.** Classes of Antiretrovirals. In: *AAHIVM Fundamentals of HIV Medicine*, 2014 Edition. Washington DC: American Academy of HIV Medicine.
21. L Battalora and **B Young.** 2014. Bone Health and HIV. In: *AAHIVM Fundamentals of HIV Medicine*, 2014 Edition. Washington DC: American Academy of HIV Medicine.
22. Hoy, J., **Young, B.** 2016. Do people with HIV infection have a higher risk of fracture compared to those without HIV infection?" *Current Opinion in HIV/AIDS.*
23. V Soriano, **B Young** and N Terrault. Report from the International Conference on Viral Hepatitis (ICVH), San Francisco, March 2016. *AIDS Reviews.*
24. **B Young.** Classes of Antiretrovirals. In: *AAHIVM Fundamentals of HIV Medicine*, 2017 Edition. Washington DC: American Academy of HIV Medicine.
25. L Battalora and **B Young.** Bone Health and HIV. In: *AAHIVM Fundamentals of HIV Medicine*, 2017 Edition. Washington DC: American Academy of HIV Medicine.

WEB-BASED JOURNAL ARTICLES

1. **B Young.** 2003. Therapeutic Challenges and New Protease Inhibitor (PI) Options in the Treatment of Antiretroviral-Naïve Patients. Posted on Medscape on October 27, 2003 at <http://www.medscape.com/viewprogram/2738>.
2. **B Young.** 2004. New HIV Protease Inhibitors. New Options in the PI Class for Treatment-Naïve Persons. Posted on TheBody.com April 2004 at <http://www.thebody.com/pwacc/spring04/pis.html>.
3. G Gray, B Gazzard, **B Young**, D Ho. 2004. Charting a Successful Course in Antiretroviral Treatment. Posted on Business Briefing: Long-term Healthcare 2004, July 2004 at <http://www.bbriefings.com>
4. **B Young.** 2006. New Antiretroviral Strategies for First-line and "Switch" Patients with HIV. Posted on Medscape.com, March 2006 at <http://www.medscape.com/viewarticle/527638>
5. **B Young** and S Kressy. 2006. Optimizing Once-daily Antiretroviral Regimens for Treatment Naïve Patients: A Case-based Approach. Posted on Medscape.com May 2006 at http://www.medscape.com/viewprogram/5426_pnt.
6. **B Young.** 2006. In Ukraine, Clinicians From East and West Battle HIV's Onslaught. Posted on TheBodypro.com Aug 2006 at <http://www.thebodypro.com/thebody/ukraine>.
7. **B Young.** 2006. HIV Drug Resistance and Resistance testing in African Americans. Posted on TheBodypro.com, July 2006
8. J Lundgren and **B Young.** 2006. Should We Embrace Proactive Therapy Switches in Patients Who Are Tolerating Their Current Regimen, Based on Concerns About Potential Long-Term Toxicity? Pro and Con Arguments. Posted on Clinical Care Options HIV, Nov 2006 [http://clinicaloptions.com/HIV/Treatment Updates/Refining Regimens.aspx](http://clinicaloptions.com/HIV/Treatment%20Updates/Refining%20Regimens.aspx)
9. **B Young** and S Kressy. 2006. When the first antiretroviral regimen fails: Management of pharmacologic/pharmacokinetic factors in persons with HIV. Posted on Medscape.com Nov 2006 at http://www.medscape.com/viewprogram/6178_pnt.
10. M Wainberg, E Daar and **B Young.** 2006. Trends and Controversies in NRTI-based ART. Posted Nov 2006 on Clinical Care Options HIV. <http://clinicaloptions.com/HIV/Resources/CME%20Options/Trends%20and%20Controversy.aspx>
11. N Vergel and **B Young.** How to Manage the Most Common Side Effects of Your First HIV Antiretroviral Regimen. Posted August 17, 2011 on TheBody.com at <http://www.thebody.com/content/63238/how-to-manage-the-most-common-side-effects-of-your.html>
12. M Helfand and **B Young.** Talking to Your Health Care Provider About HIV Treatment Adherence Issues. Posted September 1, 2011 on TheBody.com at <http://www.thebody.com/content/63735/talking-to-your-health-care-provider-about-hiv-tre.html>
13. JM Llibre and **B Young.** 10 top studies whose impact will last well beyond CROI 2013. Posted 14 March 2013 on TheBodyPro.com at <http://www.thebodypro.com/content/70878/10-top-studies-whose-impact-will-last-well-beyond.html>
14. **B Young.** Improving Engagement in HIV Care and Treatment Adherence: An Algorithmic Approach. Posted 30 April 2013 on Medscape.com. <http://www.medscape.com/viewarticle/803053>
15. **B Young.** Reflections on the 3rd International Conference on Viral Hepatitis. Posted 30 April 2013 on TheBodyPro.com. <http://www.thebodypro.com/content/71376/reflections-on-the-3rd-international-conference-on.html>
16. **B Young.** Myhivclinic.org: Rethinking how we learn to practice HIV medicine. Posted 6 May 2013 on TheBodyPro.com. <http://www.thebodypro.com/content/71433/myhivclinicorg-rethinking-how-we-learn-to-practice.html>

17. **B Young.** Improving Engagement in HIV Care and Treatment Adherence: An Algorithmic Approach. Posted 31 May 2013 on Medscape.com. <http://www.medscape.com/viewarticle/803053>
18. **B Young.** Antiretroviral therapy IS prevention. Posted 13 Jun 2013 on Medscape.com. <http://www.medscape.com/viewarticle/803053>
19. JM Llibre and **B Young.** Highlights From IAS 2013: 6 HIV-Related Studies With Major Clinical Importance. Posted 28 Aug 2013 on TheBodyPro.com. <http://www.thebodypro.com/content/72550/highlights-from-ias-2013-six-studies-with-major-cl.html>
20. **B Young.** Navigating the New Waters of the HIV Cascade, TasP and PrEP. Posted 09 Oct 2013 on Medscape.com. http://www.medscape.com/viewarticle/812188_1?src=stfb
21. **B Young.** Hypertension in a post-AIDS World. Posted 22 Nov 2013 on Medscape.com. <http://www.medscape.com/viewarticle/814666>
22. **B Young.** HIV Undetectability Unimportant? Wrong. Posted 21 Jan 2014 on TheBody.com. <http://www.thebody.com/content/73699/hiv-undetectability-unimportant-wrong.html>
23. **B Young.** Travel, migrations and the HIV Cascade. Posted 22 Jan 2014 on Medscape.com. <http://www.medscape.com/viewarticle/819504?src=stfb>
24. **B Young.** CROI 2014 Preview: Hot Topics in HIV and Hepatitis. Posted 27 Feb 2014 on TheBodyPro.com. <http://www.thebodypro.com/content/73937/croi-2014-preview-hot-topics-in-hiv-and-hepatitis-.html?getPage=1>
25. JM Llibre and **B Young.** Takeaways from CROI 2014: 7 HIV-related studies that stand out. Posted 14 Mar 2014 on TheBodyPro.com. <http://www.thebodypro.com/content/74121/takeaways-from-croi-2014-7-hiv-related-studies-tha.html>
26. **B Young.** The challenges of being a young adult with HIV. Posted March 21, 2014 on Medscape.com <http://www.medscape.com/viewarticle/822095>
27. **B Young.** Tales of two treatment worlds, fat loss, muscle loss and HIV. Posted May 2014 on Medscape.com. <http://www.medscape.com/viewarticle/825089>
28. **B Young.** Mississippi baby not cured. What next? Posted July 17, 2014 on TheBodyPro.com. <http://www.thebodypro.com/content/74734/ms-mississippi-not-cured-of-hiv-what-next.html>
29. **B Young.** Best wishes, Joep. Posted July 19, 2014 on TheBodyPro.com. <http://www.thebodypro.com/content/74764/best-wishes-joep.html>
30. **B Young.** The importance of retention in HIV care. Posted September 10, 2014 on Medscape.com <http://www.medscape.com/viewarticle/831324>
31. **B Young.** Improving the two ends of the HIV care cascade with provider-patient communication. Posted November 25, 2014 on Medscape.com <http://www.medscape.com/viewarticle/835378>
32. **B Young.** Timely interventions to improve retention in care and quality of life in HIV. Posted February 20, 2015 on Medscape.com <http://www.medscape.com/viewarticle/839954>
33. **B Young.** HIV Cure Is Nearly Impossible, But Ending Epidemic AIDS Is Entirely Possible. Posted October 12, 2015 on Medscape.com <http://www.medscape.com/viewarticle/852330>
34. **B Young.** Evidence-Based Recommendations for Improving the HIV Care Continuum: A Toolkit for Ending the AIDS Epidemic. Posted January 15, 2016 on Medscape.com <http://www.medscape.com/viewarticle/857191>

ABSTRACTS:

1. GA Freyer, J Arenas, KK Perkins, **B Young**, HM Furneaux, and J Hurwitz. 1986. Effects of specific base changes at the 3' end of the intron on mRNA splicing in vitro. Meeting on RNA processing. Cold Spring Harbor, New York.
2. KK Perkins, HM Furneaux, J Arenas, **B Young**, GA Freyer and J Hurwitz. 1986. mRNA splicing using isolated fractions from HeLa cells. Meeting on RNA processing. Cold Spring Harbor, New York.
3. **B Young** and TR Cech. 1987. A multicomponent ribozyme: methodology facilitating rapid, selective alterations in substrate specificity. Meeting on RNA processing. Cold Spring Harbor, New York.
4. J McSwiggen, S Woodson, **B Young** and TR Cech. 1988. RNA self-splicing: conformational changes, 2'-5' phosphodiester and reverse splicing. Albany conference: RNA:Catalysis, Splicing and Evolution. Albany, New York.
5. **B Young** and TR Cech. 1989. Specificity for 3'-5'-linked substrates in RNA-catalyzed RNA polymerization. Meeting on RNA processing. Cold Spring Harbor, New York.
6. **B Young** and TR Cech. 1989. Specificity for 3'-5'-linked substrates in RNA-catalyzed RNA polymerization. Graduate and medical student research forum. University of Colorado Health Sciences Center.
7. TR Cech, D Herschlag, **B Young**, AM Pyle, F Murphy, and D Celander. 1991. Mechanism and structure of a catalytic RNA molecule. FASEB annual meeting.
8. **B Young**, D Herschlag and TR Cech. 1991. Mutations in a nonconserved sequence of the Tetrahymena ribozyme increase activity and specificity. Annual MD-PhD student conference. Aspen, Colorado.
9. **B Young**, S Johnson, M Bakhtiari, D Shugarts, R Young, DR Kuritzkes. 1997. Genotypic analysis of HIV-1 protease from patients failing highly active anti-retroviral therapy: Preliminary analysis. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St. Petersburg, Florida. Abstract 65.
10. **B Young**, A Sevin, M Bakhtiari, M St. Clair, E Connick, A Landay, J Spritzler, H Kessler, MM Lederman, DR Kuritzkes for the ACTG 315 protocol team. 1998. Presence of zidovudine resistance mutations does not prevent durable viral suppression by zidovudine/lamivudine/ritonavir. Genotypic analysis from ACTG 315. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy. Abstract 50.
11. E Brown, S MaWhinney, **B Young**, S. Johnson, DR Kuritzkes, R Jones. 1998. Modeling the dynamics in viral load and CD4 lymphocyte count as a response to treatment changes. 12th World AIDS Conference. Geneva, Switzerland. Abstract 43473.
12. **B Young**, W Burman, K Lichtenstein. 1998. Initial responses to hydroxyurea in salvage antiretroviral therapy for patients with AIDS. 37th Annual Meeting, Infectious Disease Society of America. Abstract 443.
13. F Palella, A Moorman, J Chmiel, et al., 1999. Continued decline in morbidity and mortality among patients with advanced HIV infection receiving highly active antiretroviral therapy. Abstract 689. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois. Feb 99.
14. D Ward, K Lichtenstein, K Delaney, A Moorman, F Palella, **B Young**, K Wood, S Holmberg and the HOPS Investigators. 1999. Survey of clinical symptoms of fat redistribution in the HIV Outpatient Study (HOPS). Abstract 010, 1st International Workshop on HIV Lipodystrophy. Rancho Bernardo, California Jun 1999.
15. KA Lichtenstein, D Ward, K Delaney, A Moorman, F Palella, **B Young**, K Wood, S Holmberg and the HOPS Investigators. 1999. Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS). Abstract 011, 1st International Workshop on HIV Lipodystrophy. Rancho Bernardo, California Jun 1999.

16. D Ward, K Delaney, A Moorman, K Lichtenstein, F Pallela, **B Young**, K Wood, S Holmberg and the HOPS Investigators. 1999. Survey of clinical symptoms of fat redistribution in the HIV Outpatient Study (HOPS). Abstract 1298, 39th ICAAC. San Francisco, California Sep 1999.
17. D Ward, K Delaney, A Moorman, K Lichtenstein, F Pallela, **B Young**, K Wood, S Holmberg and the HOPS Investigators. 1999. Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS). Abstract 1299, 39th ICAAC. San Francisco, California Sep 1999.
18. **B Young**, PJ Harris, E Evans, M Youle, I Frank. 1999. Multicenter, randomized Phase II trial of multiple doses of lidenosine in combination with stavudine and indinavir in antiretroviral-naïve HIV-infected adults. Abstract 1925. 39th ICAAC. San Francisco, California Sep 1999.
19. KA Lichtenstein, D Ward, K Delaney, A Moorman, F Pallela, **B Young**, K Wood, S Holmberg and the HOPS Investigators. 2000. Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS). 7th Conference on Retroviruses and Opportunistic Infections, San Francisco. Jan-Feb 2000
20. **B Young**, R Baker, J Gallant, T Hawkins, K Henry, P Ruane, C Vaamonde, P Smith, K Wood, A Zolopa. 2000. Effectiveness and safety of ritonavir/indinavir containing antiretroviral therapy: A retrospective multi-center clinical cohort study. 40th ICAAC Abstract 1522; Sept. 17-20, 2000; Toronto, Canada
21. C Vaamonde, C Cohen, C Fichtenbaum, J Gallant, H Grossman, T Gulick, T Hawkins, K Henry, J Nadler, P Smith, P Tebas, **B Young**, A Zolopa. 2000. Single drug switch from protease inhibitor to non-nucleoside reverse transcriptase inhibitor-based ARV regimen: Effectiveness of maintaining viral suppression in a clinical cohort. 40th ICAAC Abstract 1540; Sept. 17-20, 2000; Toronto, Canada
22. M Watkins, M Fischl, WJ Fessel, **B Young**, N Bohidar, H Wilson, K Guckert, J Holstein, K Schneck, J Schranz. 2000. DIRECT Study: A multi-center, open-label, 24 week pilot study with a 24-week extension to evaluated the efficacy, safety and tolerability of indinavir-ritonavir 800/100 bid in combination with d4T plus 3TC in HIV-infected individuals. 40th ICAAC Abstract 544; Sept. 17-20, 2000; Toronto, Canada
23. **B Young**, M Fischl, M Watkins, WJ Fessel, N Bohidar, H Wilson, K Guckert, J Holstein, K Schneck, J Schranz. 2000. DIRECT Study: A multi-center, open-label, 24 week pilot study with a 24-week extension to evaluated the efficacy, safety and tolerability of indinavir-ritonavir 800/100 bid in combination with d4T plus 3TC in HIV-infected individuals. 5th International Congress on Drug Therapy in HIV Infection; Oct. 22-26, 2000; Glasgow, Scotland
24. **B Young**, I Frank, M Youle, R Pedro, J Madruga, D Uip, D Norris, P Salvato. 2000. Safety and efficacy of lidenosine (FddA) in combination with stavudine and indinavir in antiretroviral naïve, HIV-infected adults: Association with severe hepatotoxicity. HIV DART 2000; Frontiers in Drug Development for Antiretroviral Therapies. Dec. 17-21 2000, San Juan, Puerto Rico.
25. A Giblin, S Janty, R Weber, K Lichtenstein, **B Young**. Progressive lipodystrophy in a protease inhibitor naïve woman with an undetectable viral load off ARV therapy. 2nd European Workshop on Lipodystrophy April 19-21 2001, Cannes, France.
26. **B Young**, M Fischl, M Watkins, WJ Fessel, N Bohidar, H Wilson, K Guckert, J Holstein, K Schneck, J Schranz. 2001. DIRECT Study: A multi-center, open-label, 24 week pilot study with a 24-week extension to evaluated the efficacy, safety and tolerability of indinavir-ritonavir 800/100 bid in combination with d4T plus 3TC in HIV-infected individuals. International AIDS Society Conference on HIV Pathogenesis and Treatment. Poster 745; July 8-11, 2001, Buenos Aires, Argentina
27. **B Young**, R Baker, C Stewart, B Widick, P Zellner, K Wood. 2001. Characterization of St. John's wort use in a community clinic: Lack of association with viral breakthrough. International AIDS Society Conference on HIV Pathogenesis and Treatment. Poster 379; July 8-11, 2001, Buenos Aires, Argentina

28. H Rice, **B Young**, P Ruane, C Vaamonde, P Smith, K Henry, T Hawkins, J Gallant, P Tebas, J Nadler, C Fichtenbaum, H Grossman, M Cosam, U Murhiadshran, N Hellman, J Condra, A Japour, A Zolopa. 2001. Ritonavir (RTV) Boosting of Indinavir (IDV) Antiretroviral Regimens in Clinical Practice: Effectiveness, Safety and exploration of Phenotypic Breakpoints. International AIDS Society Conference on HIV Pathogenesis and Treatment. July 8-11, 2001, Buenos Aires, Argentina
29. E DeJesus, H Katner, D Paar, J Nadler, R Nahass, R Steigbigel, **B Young**, A Desai, E Jensen, H Wilson, J Schranz. 2001. Early treatment intervention: A Multicenter, Open-label, 24- week study to evaluate the safety and efficacy of indinavir-ritonavir 800/200 plus 2 NRTIs bid in HIV-infected individuals. International AIDS Society Conference on HIV Pathogenesis and Treatment. Poster 750; July 8-11, 2001, Buenos Aires, Argentina
30. **B Young**, M Fischl, M Watkins, R Arduino, H Wilson, C Carey, TS Finn, E Jensen, J Schranz. 2001. DIRECT Study: A multi-center, open-label, 24 week pilot study with a 24-week extension to evaluate the efficacy, safety and tolerability of indinavir-ritonavir 800/100 bid in combination with d4T plus 3TC in HIV-infected individuals (Protocol 094). 41th ICAAC Abstract 1923; Dec 16-19, 2001; Chicago, Illinois
31. H Katner, D Paar, E DeJesus, **B Young**, R Steigbigel, R Nahass, J Nadler, A Desai, E Jensen, H Wilson, J Schranz. 2001. Early treatment intervention: A Multicenter, Open-label, 24- week study to evaluate the safety and efficacy of indinavir-ritonavir 800/200 plus 2 NRTIs bid in HIV-infected individuals (Protocol 107). 41th ICAAC Abstract 1922; Dec 16-19, 2001; Chicago, Illinois
32. T Hawkins, C Geist, **B Young**, A Giblin, R Mercier, K Thornton, R Haubrich. Efavirenz (EFV) induced CNS side effects persist for one year compared to protease inhibitors (PIs). 41th ICAAC Abstract 1725; Dec 16-19, 2001; Chicago, Illinois
33. H Holland, KS Greenberg, **B Young**. Evaluation of long-term HIV seropositive survivors for presence of GBV-C. XIV International AIDS Conference. Abstract TuPeC4714. July 7-12, 2002. Barcelona, Spain.
34. JE Gallant, AE Rodriguez, W Weinberg, **B Young**, ML Lim, Q Liao, L Ross, MS Shaefer, J Johnson. Early Non-Response of Tenofovir in combination with Abacavir and Lamivudine in a Randomized Trial Comparing this Regimen to Efavirenz in Combination with Abacavir and Lamivudine: ESS30009 Unplanned Interim Analysis. 43rd ICAAC Sept. 2003; Chicago, Illinois.
35. **B Young**, R Baker, K Wood, and the HIV Outpatient Study (HOPS) Investigators. Safety and tolerability of didanosine combined with tenofovir DF in ambulatory HIV-1 infected adult individuals. 9th European AIDS Conference. Abstract F15/5. Oct 25-29, 2003. Warsaw, Poland.
36. GA McComsey, JS Huang, I Woolley, **B Young**, PE Sax, M Gerber, S Swindells, H Bonilla, G Gopalakrishnan. Fragility fractures in HIV-infected subjects: an area for improvement. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco. Feb 2004
37. **B Young**, C Armon, R Baker, P Wiedle, A Moorman, K Wood, and the HIV Outpatient Study (HOPS) Investigators. Long-term assessment of the safety and tolerability of didanosine combined with tenofovir DF in ambulatory HIV-1 infected adult individuals. Abstract WePeB5922. XV International AIDS Conference, Bangkok Thailand. July, 2004.
38. JE Gallant, AE Rodriguez, W Weinberg, **B Young**, D Berger, ML Lim, Q Liao, L Ross, J Johnson, MS Shaefer. Efficacy of Once-Daily Abacavir/Lamivudine Fixed-Dose Combination (ABC/3TC) + Efavirenz (EFV) and Subsequent Treatment of Tenofovir DF (TDF) + ABC/3TC Non-Responders (NRs): 24 Week ESS30009 Results, 44th ICAAC, Washington DC. October 2004.
39. R Baker, K Wood, **B Young**. Effects of didanosine combined with tenofovir DF on CD4+ lymphocyte levels in HIV-infected persons. European AIDS Conference. Glasgow, Scotland. November 2004.
40. JE Gallant, AE Rodriguez, W Weinberg, **B Young**, D Berger, ML Lim, Q Liao, L Ross, J Johnson, MS Shaefer. Efficacy and Safety of Once-Daily Abacavir/Lamivudine Fixed-Dose Combination (ABC/3TC) + Efavirenz (EFV) and

Subsequent Treatment of Tenofovir DF (TDF) + ABC/3TC Non-Responders (NRs): ESS30009 Planned 48 Week Analysis. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil 24-27 July 2005.

41. **B Young**, R Baker, K Wood, K Buchacz, A Moorman, S Holmberg, J Brooks for the HOPS Investigators. Changes in utilization of drug resistance testing in the HOPS cohort (1999-2003). 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil 24-27 July 2005.
42. MF Emons, J Richardson, **B Young**, R Baker. Impact of Anemia on Antiretroviral Discontinuations. International Workshop on Lipodystrophy and Adverse Effects; Dublin, Ireland. 13-16 November 2005.
43. J Eron, P Yeni, J Gathe, V Estrada, E DeJesus, S Staszewski, P Lackey, K Katlama, **B Young**, L Yau, D Sutherland-Phillips, P Wannamaker, C Vavro, L Patel, J Yeo, M Shaefer. The KLEAN Study: fosamprenavir/ritonavir versus lopinavir/ritonavir, each in combination with the abacavir/lamivudine tablet, for the initial treatment of HIV infection over 48 weeks. International AIDS Conference, Toronto, Canada. Jul 2006.
44. P. Yeni, J. Eron, B Clotet, **B. Young**, C. Vavro, L. Yau, P. Wannamaker. Resistance Analysis and Virologic Response of FPV/r BID or LPV/r BID +(ABC/3TC QD) in the KLEAN study at 48 Weeks. 46th ICAAC. Abstract H-1056. Sept 2006. San Francisco, California.
45. HY Huang, E Daar, **B Young**, A Scribner, H Wu. The roles of antiretroviral drug resistance testing and other factors in first line treatment regimen selection for HIV-infected, treatment naïve patients. 5th European Workshop on HIV Drug Resistance. March 27-30, 2007, Casais, Portugal.
46. **B Young**, K Buchacz, RK Baker, A Moorman, JS Chmiel, KC Wood, JT Brooks for the HOPS Investigators. 2007. Renal function in tenofovir–exposed and –unexposed patients receiving highly active antiretroviral therapy (HAART) in the HIV Outpatient Study (HOPS) cohort. American Conference on the Treatment of HIV Meeting. May 2007. Abstract 101. Dallas, Texas.
47. **B Young**, RK Baker, D Ward. KC Wood, JT Brooks for the HOPS Investigators. Antiretroviral resistance testing and frequency of ARV resistance among ARV-naïve patients in the HOPS cohort. 1999-2005. International Conference on Pharmacoepidemiology & Therapeutical Risk Management. Abstract 98. August 2007. Quebec City, Canada.
48. **B Young**, K Buchacz, RK Baker, A Moorman, JS Chmiel, KC Wood, JT Brooks for the HOPS Investigators. 2007. Renal function in patients with pre-existing renal disease receiving tenofovir-containing HAART in the HIV Outpatient Study (HOPS) cohort. 47th ICAAC, Chicago, IL. Sept 2007.
49. DeJesus E, **Young B**, Fisher A, Ebrahimi R, Maa J-F, Seekins D, Flaherty J, Farajallah A. Virologic suppression is maintained after change to a efavirenz/emtricitabine/tenofovir disoproxil fumarate single tablet regimen (EFV/FTC/TDF) vs continuation of current antiretroviral therapy: Study A1266073- Results of a 24-week interim efficacy analysis. Abstract LBPS7/6. 11th European AIDS Conference. Oct 2007. Madrid, Spain.
50. LL Ross, **B Young**, E DeJesus, A LaMarca, P Salvato, V Williams, R Balu, MS Shaefer for the ELECT Study. Low Incidence of Drug Resistance after Virologic Failure in HIV-1 Infected Subjects Randomized to Remain on their Current Protease Inhibitor (PI) or Switched to a Fosamprenavir Regimen for 24 Weeks (ELECT Study). 3rd International Workshop on HIV Persistence During Therapy. St. Maarten. Dec 2007.
51. **B Young**, K Squires K, P Patel, E DeJesus, ND Bellos, D Berger, D Murphy, D Sutherland-Phillips, Q Liao, P Wannamaker. Low Incidence of Suspected Abacavir Hypersensitivity (ABC HSR) after Implementation of HLA-B*5701 Screening: Results from the ARIES Study. Abstract P158. 17th Annual Conference of the Canadian Association of HIV/AIDS Research. Quebec City, Canada. April 2008.
52. **B Young**, E DeJesus, A LaMarca, P Salvato, D Sutherland-Phillips, L Yau, L Patel, P Wannamaker. Switching to fosamprenavir (FPV) led to similar efficacy and safety in HIV-1-infected subjects on their first PI regimen: a prospective, open-label, multicenter, randomized trial (ESS100290). Abstract 6209. XII International AIDS Conference. Mexico City, August 2008.

53. J Campbell, **B Young**. Utilization of screening colonoscopy in ambulatory HIV-infected patients. Abstract 629. XII International AIDS Conference. Mexico City, August 2008.
54. P Wannamaker, S Mallal, E Phillips, **B Young**, C Bothers, D Sutherland-Phillips, D Thornborn, M Schaefer. HLA B*5701 screening reduces abacavir hypersensitivity reactions (ABC HSR); multiple lines of evidence to establish a new standard of care. Abstract 629. XII International AIDS Conference. Abstract 9245. Mexico City, August 2008.
55. **B Young**, K Squires K, P Patel, E DeJesus, ND Bellos, D Berger, D Murphy, D Sutherland-Phillips, Q Liao, P Wannamaker. Low Incidence of Suspected Abacavir Hypersensitivity (ABC HSR) after Implementation of HLA-B*5701 Screening: Results from the ARIES Study. Abstract 95E. 37th Annual Meeting of the American College of Clinical Pharmacology. Louisville, Kentucky. October 2008.
56. E DeJesus, **B Young**, Fisher A, Ebrahimi R, Maa J-F, Seekins D, Flaherty J, Farajallah A. Simplification of Antiretroviral Therapy (ART) with Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF) Single-Tablet-Regimen vs. Continued Unmodified ART in Virologically-Suppressed, HIV-1-Infected Patients. Abstract 3037. ICAAC/IDSA, Washington DC. October 2008
57. **B Young**, K Smith, P Patel, M. Markowitz, D Berger, P Wannamaker, L. Yau, and C. Vavro. Characterization of Virologic Failure (VF) Over 96 Weeks by Drug Resistance and Antiviral Response in ART Naïve Patients Receiving Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) Each with Lopinavir/Ritonavir QD in the HEAT Study. Abstract H-1333. ICAAC/IDSA, Washington DC. October 2008.
58. **B Young**, R Baker, K Wood, K Buchacz, JT Brooks for the HOPS Investigators. Trends in genotypic testing among HIV-infected persons in the HOPS cohort in the United States, 1999-2006. ICAAC/IDSA, Washington DC. October 2008.
59. K Squires, **B Young**, P Patel, E DeJesus, ND Bellos, D Berger, D Murphy, D Sutherland-Phillips, Q Liao, P Wannamaker. Atazanavir/ritonavir+ abacavir/lamivudine (ABC/3TC) in antiretroviral (ART) naïve HIV-1 infected HLA-B*5701 negative subjects demonstrate efficacy and safety: the ARIES trial. Abstract H-1250a. ICAAC/IDSA, Washington DC. October 2008.
60. C Cohen, E DeJesus, L Lamarca, **B Young**, D Sutherland-Phillips, L Dix, L Patel, C Valvo, P Wannamaker, M Shaefer. Switching from a 200mg-ritonavir-boosted fosamprenavir regimen to a 100 mg RTV-boosted FPV regimen yields similar efficacy and safety. ICAAC/IDSA, Washington DC. October 2008.
61. **B Young**, E DeJesus, JO Morales-Ramirez, R Ebrahim, JF Maa, D McColl, A Farajallah, D Seekins, J Flaherty. Simplification of Antiretroviral Therapy (ART) with Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF) Single-Tablet-Regimen vs. Continued Unmodified ART in Virologically Suppressed, HIV-1-Infected Patients. Abstract P061. 9th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland. November 2008.
62. J Eron, J Andrade, R Zajdenverg, C Workman, D Cooper, **B Young**, X Xu, B-Y Nguyen, R Leavitt, P Sklar. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination antiretroviral therapy resulted in superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. Abstracts, Conference on Retroviruses and Opportunistic Infections. Feb 2009. Montreal, Canada.
63. Novak RM, Richardson JT, Buchacz K, Chmiel JS, Durham M, Palella FJ, Wendrow A, Wood K, **Young B**, Brooks JT and the HOPS Investigators. Risk Factors for and Manifestations of Immune Restoration Inflammatory Syndrome (IRIS) in the HIV Outpatient Study (HOPS), 1996-2007. 13th International Workshop on HIV observational databases in Lisbon, March 2009.
64. J Campbell, AL Ruano, DL Estrado, B Samayoa, E Arathoon, **B Young**. Adherence to antiretroviral therapy in an urban, free-care HIV clinic in Guatemala City, Guatemala. 4th International Conference on HIV Treatment Adherence. Miami, Florida. Abstract 0272. April 2009.

65. DeJesus E, **Young B**, Fisher A, Ebrahimi R, Maa J-F, Seekins D, Flaherty J, Farajallah A. Simplification of Antiretroviral Therapy (ART) with Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF) Single-Tablet-Regimen vs. Continued Unmodified ART in Virologically-Suppressed, HIV-1-Infected Patients. 18th Annual Conference of the Canadian Association of HIV/AIDS Research. April 2009.
66. K Squires, **B Young**, E DeJesus, N Bellos, D Murphy, D Sutherland-Phillips, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV, r), each in combination with abacavir/lamivudine (ABC/3TC), after initial suppression with ABC/3TC + ATV/r in HIV-1 infected patients: 84 week results of the ARIES trial. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Abstract WELBB103. Cape Town, South Africa. July 2009.
67. **B Young**, T Vanig, E DeJesus, T Hawkins, M St. Clair, L Lau, B Ha and the SHIELD study investigators. Framingham Risk and Lipoprotein Changes after 24 weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral (ARV) Naïve HIV-1 Infected Subjects. 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. Philadelphia, Pennsylvania. October 2009.
68. **B. Young**, T. Vanig, E. DeJesus, T. Hawkins, M. St. Clair, L. Yau, B. Ha, and the SHIELD study team. A pilot study of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naïve HIV-1 infected subjects. 12th European AIDS Conference. Cologne, Germany. November 2009.
69. C Dao, **B Young**, K Buchacz, R Baker, JT Brooks. Higher and Increasing Rates of Fracture among HIV-infected Persons in the HIV Outpatient Study (HOPS) Compared to the General U.S. Population, 1994-2008. Abstract 128. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. February 2010.
70. LL Ross, K Squires, **B Young**, E Dejesus, N Bellos, D Murphy, A Rachlis, H Zhao, L Patel, P Wannamaker and M Shaeffer. Genotypic Screening Impact in ARIES [Atazanavir (ATV) + Ritonavir (r)+Abacavir/Lamivudine (ABC/3TC) for 36 Weeks Followed By Randomization to ATV+ABC/3TC or ATV/r + ABC/3TC for 48 Wks in HIV-infected, ART Naïve Patients]: Low Rates of Virologic Failure. 19th Annual Canadian Conference on HIV/AIDS Research. 13-19 May, 2010. Saskatoon, Canada.
71. S Fransen, **B Young**, KS Greenberg, A Thomas, S Martens, M St Clair, CJ Petropoulos, B Ha. Transmission of integrase strand-transfer inhibitor multi-drug resistant HIV: case report and natural history of response to raltegravir-containing antiretroviral therapy. Abstract 56. International HIV and hepatitis drug resistance workshop and curative strategies. Dubrovnik, Croatia. 8-12 June 2010.
72. B Clotet, C Katlama, J Lalezari, **B Young**, J Huang, M Underwood, M Ait-Khaled, G Nichols. HIV integrase resistance profiles and S/GSK1349572 baseline phenotypic susceptibility for subjects experiencing virologic failure on raltegravir (RAL) and enrolling in the VIKING phase IIb pilot study (ING112961). Abstract 50. International HIV and hepatitis drug resistance workshop and curative strategies. Dubrovnik, Croatia. 8-12 June 2010.
73. **B Young**, S Fransen, KS Greenberg, A Thomas, S Martens, M St Clair, CJ Petropoulos, B Ha. Transmission of integrase strand-transfer inhibitor multi-drug resistant HIV: case report and natural history of response to raltegravir-containing antiretroviral therapy. XVIII International AIDS Conference. Vienna, Austria. 18-23 July 2010.
74. **B Young**, T. Vanig, E. DeJesus, T. Hawkins, M. St. Clair, L. Yau, B. Ha, and the SHIELD study team. A pilot study of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naïve HIV-1 infected subjects. Abstract TUPE0163. XVIII International AIDS Conference. Vienna, Austria. 18-23 July 2010.
75. S. Brewer, A Jienbekova, R Maxudov, V Fuller, **B Young**. Combining Tradition & Innovation to Improve Professional Capacity in Central Asia. XVIII International AIDS Conference. Vienna, Austria. 18-23 July 2010.
76. V Tye, A Kutmanova, **B Young**. Initial antiretroviral therapy administration in Kyrgyzstan (2005-2008). Abstract CDB0162. XVIII International AIDS Conference. Vienna, Austria. 18-23 July 2010.
77. J Arribas, A Lazzarin, F Raffi, A Rakhmanova, G Richmonds, J Rockstroh, J van Lunzen, **B Young**, S Almond, C Bothers, S Min, G Nichols for the extended SPRING-1 team. Once-daily S/GSK1349572 as part of combination

- therapy in antiretroviral naïve adults: Rapid and potent antiviral responses in the interim 16-week analysis from the SPRING-1 (ING1 12276). XVIII International AIDS Conference. Vienna, Austria. 18-23 July 2010.
78. K Squires, E DeJesus, N Bellos, D Ward, D Murphy, **B Young**, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV, r), each in combination with abacavir/lamivudine (ABC/3TC), after initial suppression with ABC/3TC + ATV/r in HIV-1 infected patients: 120-week results of the ARIES trial. Abstract H-204. 50th ICAAC, Boston, Massachusetts. 12-15 September 2010.
 79. **B Young**, T Vanig, E DeJesus, T Hawkins, M St. Clair, L Yau, B Ha, and the SHIELD study team. SHIELD: 48 week results of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naïve HIV-1 infected subjects. Abstract 116E. American College of Clinical Pharmacy Annual Meeting, Austin, Texas, United States. October 2010.
 80. K Buchacz, R Baker, DJ Ward, FJ Palella, JS Chmiel, **B Young**, BG Yangco, RM Novak, JT Brooks. Frequency of Antiretroviral Resistance among ARV-experienced Patients in the HIV Outpatient Study (HOPS): 1999-2008. 15th International Workshop on HIV Observational Databases. Prague, Czech Republic. March 2011.
 81. LL Ross, K Squires, **B Young**, E DeJesus, N Bellos, D Murphy, H Zhao, E Blackmon, B Wine, J Horton, M Shaefer. Ultra-deep HIV-1 sequencing analysis from subjects experiencing virological failure in the ARIES study: assessment of the impact of low-abundance HIV-1 variants on resistance mutation selection pathways. Abstract 61. *Antiviral Therapy 2011*; 16 suppl 1:A77. International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies. Los Cabos, Mexico, 7-11 June 2011
 82. LL Ross, K Squires, **B Young**, E DeJesus, N Bellos, D Murphy, H Zhao, E Blackmon, B Wine, J Horton, M Shaefer. Pre-therapy detection of transmitted low-abundance HIV-1 resistance mutation-containing variants in antiviral-naïve subjects and implications for subsequent clinical therapy response. Abstract 88. *Antiviral Therapy 2011*; 16 suppl 1:A109. International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies. Los Cabos, Mexico, 7-11 June 2011
 83. K Squires K, **B Young**, E DeJesus, N Bellos, D Murphy, H Zhao, LL Ross, M Shaefer. Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV), each in combination with abacavir/lamivudine (ABC/3TC), after initial suppression with ABC/3TC + ATV/RTV in HIV-1 infected patients: final (144 weeks) results of the open-label, multicenter, non-inferiority ARIES study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome, Italy. Abstract MOPE215.
 84. **B Young**, K Squires, LL Ross, L Santiago, L Sloan, H Zhao, B Wine, M Schultz, D Margolis, M Shaefer. Changes in Inflammatory Biomarker Levels, including Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Levels and Correlation with Framingham (FRAM) Risk Scores in Antiretroviral (ART)-Naïve Patients through 144 week of Abacavir/Lamivudine (ABC/3TC) Containing Therapy in the Open-label, Multicenter, Non-inferiority ARIES Study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome, Italy.
 85. J van Lunzen, F Maggiolo, B Phung, O Tsybakova, **B Young**, J Gatell, S Almond, M St Clair, C Brothers, S Min. Rapid, Robust and Sustained Antiviral Response with Once-daily (QD) Dolutegravir (DTG, S/GSK1349572), a Next Generation Integrase Inhibitor (INI) in Combination Therapy in Antiretroviral-naïve Adults. 48 Week Results from SPRING-1 (ING112276). 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome, Italy.
 86. **B Young**, T Vanig, E DeJesus, T Hawkins, M St.Clair, B Stancil, B Ha and the SHIELD study team. Long-Term Efficacy and Safety of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Subjects. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome, Italy. Abstract CDB276
 87. L Ross, K Squires, **B Young**, E DeJesus, N Bellos, D Murphy, H Zhao, B Wine, J Horton, M Shaefer. Pre-therapy detection of transmitted low-abundance HIV-1 resistance mutation-containing variants in antiviral-naïve subjects and implications for subsequent clinical therapy response. 51th ICAAC, Chicago, Illinois. 17-20 September 2011. Abstract H2-796.

88. L Ross, K Squires, **B Young**, E Dejesus, N Bellos, D Murphy, H Zhao, B Wine, J Horton, M Shaefer. Comparison of population genotype and ultradeep sequencing results from subjects with virologic failure in ARIES: Impact of low-abundance HIV variants on outcome. 51th ICAAC, Chicago, Illinois. 17-20 September 2011. Abstract H2-797.
89. **B Young**, KE Squires, K Tashima, K Henry, S Schneider, A LaMarca, HH Zhao, LL Ross, MS Shaefer for the ARIES Study Team. Estimated glomerular filtration rate (eGFR) through 144 weeks on therapy in HIV-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. Abstract PO34. 14th International Workshop on Comorbidities and Adverse Drug Reactions in HIV. July 19-21, 2012; Washington DC.
90. E Tedaldi, J Richardson, **B Young**, JS Chmiel, MD Durham, JT Brooks, K Buchacz, and the HOPS Investigators. Do patients achieve a minimal standard of continuous HIV care: analyses from a multisite US cohort. XIX International AIDS Conference (AIDS 2012). Washington D.C., 22-27 July 2012. Poster WEPE120
91. L Battalora, J Spears, **B Young**. HIV and Aging: An Evolving Challenge for the Oil and Gas Industry. SPE/APPEA International Conference on Health, Safety and Environment in Oil and Gas Exploration and Production (2012 HSE), 11-13 September 2012. Perth, Australia.
92. K Buchacz, **B Young**, FJ Palella, C Armon, JT Brooks for the HIV Outpatient Study Investigators. Trends in genotypic testing use and results among antiretroviral-naïve patients in the HIV Outpatient Study. 20th Conference on Retroviruses and Opportunistic Infections. 3-6 March 2013, Atlanta, Georgia. Abstract 615.
93. L Battalora, K Buchacz, C Armon, ET Overton, J Hammer, P Patel, JS Chmiel, TJ Bush, JT Brooks, **B Young**, the HIV Outpatient Study (HOPS), SUN Study Investigators. Low bone mineral density is associated with increased risk of incident fracture in HIV-infected adults. 14th European AIDS Conference. October 2013, Brussels, Belgium. *Antiviral Therapy* 2013;18 Suppl 3:A24.
94. L Battalora, K Buchacz, C Armon, ET Overton, J Hammer, P Patel, JS Chmiel, TJ Bush, JT Brooks, **B Young**, the HIV Outpatient Study (HOPS), SUN Study Investigators. New Fracture Risk and FRAX 10-Year Probability of Fracture in HIV-infected Adults. 21st Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. March 2014.
95. L Battalora, K Buchacz, C Armon, ET Overton, J Hammer, P Patel, JS Chmiel, TJ Bush, JT Brooks, **B Young**, the HIV Outpatient Study (HOPS), SUN Study Investigators. Low bone mineral density is associated with increased risk of incident fracture in HIV-infected adults. 21st Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. March 2014.
96. L Battalora, K Buchacz, C Armon, ET Overton, J Hammer, P Patel, JS Chmiel, TJ Bush, JT Brooks, **B Young**, the HIV Outpatient Study (HOPS), SUN Study Investigators. New Fracture Risk and FRAX 10-Year Probability of Fracture in HIV-infected Adults. International Society of Pharmacoeconomics and Outcomes Research 19th International Meeting. Montreal, Quebec, Canada May 2014.
97. L Battalora, K Buchacz, C Armon, ET Overton, J Hammer, P Patel, JS Chmiel, TJ Bush, JT Brooks, **B Young**, the HIV Outpatient Study (HOPS), SUN Study Investigators. Low bone mineral density is associated with increased risk of incident fracture in HIV-infected adults. International Society of Pharmacoeconomics and Outcomes Research 19th International Meeting. Montreal, Quebec, Canada May 2014.
98. **B Young**, M Kurian, I Sidibe, JSG Montaner, J Zuniga. Global Clinician Perceptions of Antiretroviral Therapy (ART): Results of a 2014 IAPAC/IAS Clinician Survey. 20th International AIDS Conference. Melbourne, Australia. 20-25 July 2014.
99. **B Young**, M Kurian, I Sidibe, JSG Montaner, J Zuniga. Global Clinician Perceptions of Treatment as Prevention (TasP): Results of a 2014 IAPAC/IAS Clinician Survey. 20th International AIDS Conference. Melbourne, Australia. 20-25 July 2014.

100. **B Young**, R Debes, K Buchacz, M Scott, F Palella, JT Brooks. HIV viral load monitoring frequency and risk of treatment failure among immunologically stable HIV-infected patients prescribed ART. 20th International AIDS Conference. Melbourne, Australia. 20-25 July 2014.
101. K Buchacz, C Armon, E Tedaldi, F Palella, R Novak, D Ward, **B Young**, R Debes, M Durham, J Brooks. Disparities in HIV viral load suppression among MSM, the HIV Outpatient Study, 2013. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 23-26 Feb, 2015.
102. L Battalora, K Buchacz, C Armon, J Hammer, JS Chmiel, JR Speer, JT Brooks, **B Young**, ET Overton, the HIV Outpatient Study (HOPS), SUN Study Investigators. Osteoporosis and fractures in HIV-infected adults: Who is afraid of the Lumbar Spine?" 23rd Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. March 2016.
103. L Battalora, C Armon, K Buchacz, J Hammer, J Spear, JT Brooks, **B Young**, ET Overton. FRAX-tool fracture risk comparison: Have a little backbone. 24rd Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. February 2017.

OTHER BRIEF COMMUNICATIONS

1. **B Young**. HIV is still a concern. Posted 30 Nov 2010 on summitdaily.com. <http://www.summitdaily.com/article/20101130/COLUMNS/101129826&>
2. **B Young** and D Cohn. July is national HIV awareness month: Stigma remains a barrier to treatment despite medical advances. Posted 12 July 2012 on huffingtonpost.com. http://www.huffingtonpost.com/benjamin-young-md/hivaids-awareness_b_1669495.html
3. R Kuhn and **B Young**. HIV Cure: Game changer or just a lucky little girl. Posted 10 Marc 2013 on Globalpost.com. <http://www.globalpost.com/dispatches/globalpost-blogs/commentary/hiv-cure-science-health-technology-US>
4. M Scott and **B Young**. Colorado in a post-AIDS world. Posted 3 Dec 2013 on denverpost.com <http://blogs.denverpost.com/opinion/2013/12/03/colorado-in-a-post-aids-world/42310/>